METABOLIC & BARIATRIC SURGERY

Vol. 2, Issue 13   |   October 6, 2026

A state scorecard of obesity treatment access, weight recurrence after RYGB, five-year esophagitis after sleeve, and gaps in nutritional follow-up lead this week's surgical coverage. New drug trials sharpen the distinction between weight-loss efficacy, tolerability and proven cardiovascular benefit.

A — Metabolic Surgery Research

Scott JD, Hale AL, Zvenyach T, Nadglowski J, Hilton LR | Surgery for Obesity and Related Diseases, 2026 | 10.1016/j.soard.2026.09.020

Disclosure: Production Editor John D. Scott is the first author of this paper.

Scott and colleagues scored 50 states and DC using 44 measures of obesity treatment access. This ecological, cross-sectional analysis yielded a mean score of 48.5 out of 100, ranging from 25.5 to 77.7. No jurisdiction reached the authors' A threshold of 80, although two earned A-minus grades; the investigator-defined framework remains exploratory rather than a validated access measure.

For bariatric programs, the scorecard can help organize questions about coverage and local service capacity. State averages cannot tell a surgeon whether an individual patient can obtain treatment, and data lag matters when coverage changes. Before using a grade in advocacy or contracting, check the underlying policy and separate measured access barriers from population disadvantage.

CLINICAL IMPLICATION

Use the scorecard to frame questions about coverage and service capacity in your state, then confirm the current policy directly. Stable rankings under alternative weights do not establish patient-level validity.

Olmi S, Delcarro A, Ciccarese F et al. | Surgical Endoscopy, 2026 | 10.1007/s00464-026-13391-3

Editor's note: Revisited from MBS Digest Vol. 2, Issue 11 at the Editorial Board's request.

Olmi and colleagues studied 400 consecutive sleeve patients; 356 had a five-year endoscopy, including all 115 with an identified hiatal hernia. Esophagitis occurred in 4/75 patients with repair (5.3%) versus 9/40 without repair (22.5%). The crude odds ratio was 0.19 (95% CI 0.06–0.68); baseline-stratified analysis supported the association, but repair was selective rather than randomized.

All 44 patients missing endoscopy came from the no-hernia group, not the repair comparison. Surgeons routinely repaired defects of at least 2 cm, but smaller defects depended on surgical judgment; exact defect size was not recorded, and patient-level multivariable adjustment was unavailable. These limitations prevent a causal prevention claim or a reliable repair size threshold.

KEY FINDING

The five-year association supports repairing a hiatal hernia identified at the time of sleeve. It does not establish a causal protective effect or a size threshold for repair.

Mera-Carreiro S, Ramos-Leví A, Matía-Martín P et al. | Obesity Surgery, 2026 | 10.1007/s11695-026-08954-1

A retrospective study of 98 patients without diabetes compared liraglutide prescribed at 3 mg (43 patients) with argon plasma coagulation, APC (55), for weight recurrence after RYGB. Reported 24-month mean total weight loss was 15.59% versus 7.03%, with follow-up of 79.1% versus 76.4%. Treatment reflected clinical factors, insurance, and preference; the authors did not perform propensity score matching or intention-to-treat imputation.

Both options belong in the discussion: a patient regaining weight after bypass, and cost shapes the choice; seven patients stopped liraglutide because of it. Mean dose was 2.7 mg/day; 49% had GI effects during titration, and none stopped for them. APC took a median of three sessions, with grade I complications in seven. Selection and attrition limit the comparison.

CLINICAL IMPLICATION

Liraglutide was associated with greater sustained weight loss than APC in this cohort. Selection bias limits any claim of superiority, especially beyond these specific treatments.

Holt G, Abbott S, Price C et al. | Obesity Surgery, 2026 | 10.1007/s11695-026-08960-3

A retrospective audit of 669 patients at 13 English bariatric centers found uneven nutritional monitoring during the first postoperative year. Among follow-up attendees, clinicians requested blood tests for 33.7% at three months, 60.0% at six months, and 88.4% at 12 months. Deficiencies were frequent among tested patients, but extensive missing data and selective testing limit prevalence estimates.

The immediate quality-improvement target is reliable testing and review, not a new supplement dose. Programs should check whether laboratory orders, completed tests, and corrective treatment remain connected after virtual visits. Procedure comparisons were unadjusted, and supplementation adherence was self-reported; neither supports assuming that sleeve patients need less nutritional surveillance.

CLINICAL IMPLICATION

An attended appointment did not reliably lead to a blood-test request. Audit early follow-up workflows before treating the reported deficiency rates as estimates for all postoperative patients.

B — Science of Obesity Metabolism

Jastreboff AM, Kaplan LM, Davies MJ et al. | The New England Journal of Medicine, 2026 | 10.1056/NEJMoa2604169

Lilly-funded TRIUMPH-1 randomized 2,339 adults without diabetes to weekly retatrutide or placebo in a double-blind phase 3 trial. At 80 weeks, the 12-mg group had 25.0% mean weight loss versus 3.9% with placebo under the treatment-regimen estimand. That analysis accounted for treatment discontinuation; knee-pain and sleep-apnea primary analyses used a different, hybrid estimand.

These results inform discussions about investigational therapy, but the trial did not compare retatrutide with surgery or another active drug. Adverse events led to treatment discontinuation in 11.1% assigned to 12 mg versus 4.6% with placebo. Gastrointestinal symptoms and dose reductions matter alongside the weight result, and this study was not powered to establish cardiovascular safety.

KEY FINDING

The 25.0% result is the 80-week treatment-regimen estimate, not the larger efficacy-estimand estimate. It should not be presented as evidence that retatrutide matches surgery.

Wharton S, le Roux CW, Startseva E et al. | The New England Journal of Medicine, 2026 | 10.1056/NEJMoa2607219

Boehringer Ingelheim's SYNCHRONIZE-2 randomized 752 adults with type 2 diabetes and a BMI of 27 or more, none taking insulin, to weekly survodutide 3.6 mg or 6.0 mg or placebo. At 76 weeks, the primary analysis showed 8.2% and 9.8% mean weight loss versus 3.9% with placebo; assuming everyone stayed on treatment, 10.4% and 13.1%. HbA1c fell 0.9 and 0.8 points from 7.4%, versus 0.2.

Counsel patients with diabetes to expect about 10% weight loss at the higher dose, less than the 13.0% seen without diabetes. Gastrointestinal events, mainly during dose escalation, led 18% to stop survodutide, versus 1.2% on placebo. Hypoglycemia occurred in 8% to 9% versus 4%; the one severe episode involved a sulfonylurea, so review those doses at initiation.

CLINICAL IMPLICATION

The primary result is 9.8% weight loss at 6.0 mg; the widely quoted 13.1% assumes everyone stayed on treatment. Survodutide remains investigational, and this trial did not compare it with semaglutide or tirzepatide.

Garvey WT, Ard J, Connery L et al. | The Lancet Diabetes & Endocrinology, 2026 | 10.1016/S2213-8587(26)00213-5

Zealand-funded ZUPREME 1 randomized 493 adults without type 2 diabetes to weekly petrelintide or placebo; 485 received treatment. In this double-blind phase 2 trial, mean weight loss was 9.8% with 5 mg versus 1.7% with placebo at the 28-week primary endpoint (efficacy estimand). Loss reached 10.7% at week 42, an exploratory endpoint; nausea affected 20% across pooled active doses versus 6% with placebo.

For patients who stop incretins because of nausea, an amylin-only drug is worth watching, but this trial cannot show it is better tolerated: there was no active comparator. Participants were blinded to drug versus placebo but not to dose, because escalation schedules differed. Phase 3 data are needed before counseling patients on its weight loss or gastrointestinal profile.

KEY FINDING

The primary result belongs to week 28; the week-42 result is exploratory. Nausea was more common than with placebo, and without a head-to-head trial, better tolerability than GLP-1 drugs is unproven.

Klein KR, Wysham C, Tuttle KR et al. | The Lancet, 2026 | 10.1016/S0140-6736(26)01865-9

Lilly-funded ACHIEVE-4 randomized 2,749 adults with type 2 diabetes and elevated cardiovascular risk to oral orforglipron or insulin glargine. Over a median of two years, the open-label trial met its MACE-4 noninferiority endpoint. The stratified hazard ratio was 0.84 (95% CI 0.59–1.20); its upper confidence limit was below the prespecified noninferiority margin of 1.8.

The safety result should not be turned into a claim that orforglipron prevents cardiovascular events. Gastrointestinal adverse events were more common than with glargine, while clinically significant or severe hypoglycemia was less common. For high-risk patients, those trade-offs matter, but exploratory mortality findings were not multiplicity-controlled and do not justify a survival-benefit claim.

KEY FINDING

MACE-4 occurred in 4.2% versus 5.0% in the primary analysis populations. The confidence interval supports the specified noninferiority conclusion, not proven cardiovascular risk reduction.

C — Metabolic Innovation and Technology

AAFP, AAP, ACOG, ACP, ACS and AMA | American Medical Association, September 30, 2026 | Source ↗

A joint statement from six physician organizations, including the ACS and AMA, rejects claims that AI should displace physician judgment. The organizations argue that patient context, professional accountability, and trust must guide adoption. This is a policy position, not a clinical study, and it provides no comparative evidence that any AI tool improves bariatric outcomes.

For a bariatric service weighing AI for documentation, triage, or risk prediction, name the clinician who reviews each output and owns the decision. Pilot the tool on your own patients and workflow before expanding use, track where it errs, and set an escalation path for when it is wrong. These steps are our suggestions; the statement itself offers no validation protocol.

CLINICAL IMPLICATION

AI support does not transfer clinical accountability away from the treating team. Judge each proposed tool by its intended use and verified performance, not broad claims about machine expertise.

D — Metabolic Marketplace

Novo Nordisk | Novo Nordisk Newsroom, September 29, 2026 | Source ↗

Novo Nordisk's September 29 announcement describes a licensing agreement with Hengrui for HRS-1596, a phase 1-ready oral GLP-1/GIP agonist. The deal includes $300 million upfront within a potential $2.6 billion total tied to milestones, plus royalties. Rights exclude mainland China, Hong Kong, Macao and Taiwan; closing remains subject to antitrust clearance and other customary conditions.

When patients ask about a once-weekly GLP-1 pill, the accurate answer is that this one has not yet been tested in people; Hengrui has clearance to begin phase 1 trials in China. Weight loss, tolerability, and price are all unknown, so it should not delay surgery or current drug therapy. Track it as a sign that less frequent oral dosing is a major industry target.

CLINICAL IMPLICATION

The proposed dosing schedule still needs clinical testing. The headline deal value includes contingent payments and does not establish efficacy, affordability or availability.

Ascletis Pharma Inc. | Ascletis Pharma / PR Newswire, October 2, 2026 | Source ↗

Ascletis reported animal findings for its amylin/GLP-1/GIP combination ASC36_35FDC in an October 2 release about EASD 2026. In diet-induced obese rats, the company reported 24.8% weight loss at day 14 with dosing every two days. Primate pharmacokinetics, a separate experiment, informed the proposed longer dosing intervals; the release did not report animal sample sizes.

If a patient brings this release to clinic, the key point is that the 24.8% figure came from rats over two weeks, not people. Monthly or quarterly dosing is a target projected from primate drug levels, and the release reports no human data. It should not influence current choices between surgery and available medications, though the triple-hormone approach is worth following.

KEY FINDING

The reported rat weight loss followed seven doses given every two days. Neither that experiment nor primate half-life estimates establish monthly or quarterly efficacy in humans.

Closing the gaps in knowledge...

Production Editor John D. Scott MD FACS | [email protected]

This issue's ballot: 6 of 6 board seats voted.

MBS Digest | October 6, 2026 | Vol. 2, Issue 13

For educational purposes only.